148 related articles for article (PubMed ID: 38194617)
21. Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
Kontbay T; Şıklar Z; Özsu E; Uyanık R; Bilici E; Ceran A; Berberoğlu M
Turk J Pediatr; 2022; 64(5):892-899. PubMed ID: 36305439
[TBL] [Abstract][Full Text] [Related]
22. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
23. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
[TBL] [Abstract][Full Text] [Related]
24. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
Burlacu MC; Maiter D; Duprez T; Delgrange E
Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
[TBL] [Abstract][Full Text] [Related]
25. Resistant prolactinomas: a case series of 26 patients.
Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
[TBL] [Abstract][Full Text] [Related]
26. Prolactinomas and menopause: any changes in management?
Greenman Y
Pituitary; 2020 Feb; 23(1):58-64. PubMed ID: 31686376
[TBL] [Abstract][Full Text] [Related]
27. Phenotype and resistance patterns of 10 resistant prolactinomas.
Araujo-Castro M; Abad López A; Aller Pardo J; Kanaan Kanaan L; Palacios García N
Endocrinol Diabetes Nutr (Engl Ed); 2020 Mar; 67(3):194-204. PubMed ID: 31201099
[TBL] [Abstract][Full Text] [Related]
28. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
29. High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?
Espinosa-Cárdenas E; Sánchez-García M; Ramírez-Rentería C; Mendoza-Zubieta V; Sosa-Eroza E; Mercado M
Endocrine; 2020 Oct; 70(1):143-149. PubMed ID: 32548734
[TBL] [Abstract][Full Text] [Related]
30. Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
Hacisahinogullari H; Canturk S; Dogansen S; Yarman S
J Fr Ophtalmol; 2022 May; 45(5):511-518. PubMed ID: 35272874
[TBL] [Abstract][Full Text] [Related]
31. Start low, go slowly - mental abnormalities in young prolactinoma patients under cabergoline therapy.
Brichta CM; Wurm M; Krebs A; Schwab KO; van der Werf-Grohmann N
J Pediatr Endocrinol Metab; 2019 Sep; 32(9):969-977. PubMed ID: 31323004
[TBL] [Abstract][Full Text] [Related]
32. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
[TBL] [Abstract][Full Text] [Related]
33. Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline.
Biagetti B; Sarria-Estrada S; Ng-Wong YK; Martinez-Saez E; Casteràs A; Cordero Asanza E; Hernandez I; Giralt-Arnaiz M; Simò R
Eur J Endocrinol; 2021 Sep; 185(4):587-595. PubMed ID: 34374649
[TBL] [Abstract][Full Text] [Related]
34. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Tirosh A; Benbassat C; Shimon I
Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
[TBL] [Abstract][Full Text] [Related]
35. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
[TBL] [Abstract][Full Text] [Related]
36. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
37. Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma.
Kim K; Park YW; Kim D; Ahn SS; Moon JH; Kim EH; Lee EJ; Ku CR
J Clin Endocrinol Metab; 2021 Jan; 106(2):e615-e624. PubMed ID: 33079168
[TBL] [Abstract][Full Text] [Related]
38. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
39. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Yarman S; Kurtulmus N; Bilge A
Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
[TBL] [Abstract][Full Text] [Related]
40. Approach to the Patient With Prolactinoma.
Auriemma RS; Pirchio R; Pivonello C; Garifalos F; Colao A; Pivonello R
J Clin Endocrinol Metab; 2023 Aug; 108(9):2400-2423. PubMed ID: 36974474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]